EGFR and non-small cell lung carcinoma: On 12 January 2018, the Food and Drug Administration (FDA) granted approval to afatinib for a broadened indication in the first‐line treatment of patients with metastatic NSCLC whose tumors had nonresistant EGFR mutations as detected by an FDA‐approved test.